Global Epilepsy Drugs Market Size study & Forecast, by Drugs (First Generation Anti-epileptics, Second Generation Anti-epileptics, Third Generation Anti-epileptics), by Distribution Channel (Hospital Pharmacy, Pharmacy Stores, Others) and Regional Analysi

Global Epilepsy Drugs Market Size study & Forecast, by Drugs (First Generation Anti-epileptics, Second Generation Anti-epileptics, Third Generation Anti-epileptics), by Distribution Channel (Hospital Pharmacy, Pharmacy Stores, Others) and Regional Analysis, 2023-2030

Global Epilepsy Drugs Market is valued at approximately USD XXX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XXX% over the forecast period 2023-2030. Epilepsy is a neurological disorder characterized by recurrent seizures, and there are many drugs available to treat this condition. The choice of medication depends on the type of epilepsy, the age of the patient, and other factors such as the patient's overall health and the presence of other medical conditions. However, the market for epileptic drugs is growing as a result of an increase in the number of persons who suffer from epilepsy. A widespread neurological illness, epilepsy is a major market-driving factor due to the rise in prevalence of the condition globally. Additionally, epilepsy is affecting more people due to factors like population growth, ageing populations, and improved diagnosis, all of which contribute to the market's expansion. For instance, epilepsy incidence rates rise with age and are highest in people over the age of 75, according to a report released by UpToDate Inc. in August 2021. As a result, the demand for epilepsy drugs is driven by the rising prevalence of epilepsy among the senior population, which is supporting market growth.

Moreover, the rise in new drug approvals by the government authority is anticipated to create a lucrative demand for the market during forecast period. For instance, In March 2022, The United States Food and Drug Administration granted Lupin's abbreviated new drug application (ANDA) for Vigabatrin approval. It is an anti-epileptic drug that will be sold as a 500 mg oral solution USP. Also, In March 2022, The US Food and Drug Administration approved the drug Ztalmy from Marinus Pharmaceuticals to treat seizures in people with CDKL5 deficiency, a genetic form of epilepsy. As a result, the rising drug approvals are anticipated to support the market growth during projected period. Additionally, rising research and development activities related to epilepsy drugs is anticipated to create a lucrative opportunity for the market during forecast period. However, the side effects associated with the drugs stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Epilepsy Drugs Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the presence of key market players, rising burden of epilepsy coupled with the strategic initiatives, awareness campaigns, and development of new products by the market players in the region. Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as rising geriatric population, growing prevalence of epilepsy, and the presence of high unmet medical needs in emerging economies of India and China.

Major market players included in this report are:
Novartis AG
GlaxoSmithKline plc
Sanofi S.Aa
UCB S.A.
Abbott Laboratories
Bausch Health Companies, Inc
Viatris Inc.
Johnson & Johnson
Sumitomo Pharma Co., Ltd
H. Lundbeck A/S

Recent Developments in the Market:
In Nov. 2020, According to UCB S.A., a global pharmaceutical company, the U.S. Food and Drug Administration (FDA) has approved both VIMPAT (lacosamide) CV and VIMPAT injection for intravenous use in children four years of age and older for the treatment of primary generalised tonic-clonic seizures (PGTCS).

Global Epilepsy Drugs Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Drugs, Distribution Channel, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa


The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Drugs:
First Generation Anti-epileptics
Second Generation Anti-epileptics
Third Generation Anti-epileptics

By Distribution Channel:
Hospital Pharmacy
Pharmacy Stores
Others

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Novartis AG
GlaxoSmithKline plc
Sanofi S.Aa
UCB S.A.
Abbott Laboratories
Bausch Health Companies, Inc
Viatris Inc.
Johnson & Johnson
Sumitomo Pharma Co., Ltd
H. Lundbeck A/S

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.